A new nationwide lung cancer screening program will launch in Germany in 2026 for high-risk statutory insurance holders. The HANSE study demonstrates how risk groups can be identified more precisely—allowing significantly more cancer cases to...
A new bioinformatic tool combines the IASLC algorithm with genetic data analysis to more reliably distinguish primary lung tumors from metastases, supporting more accurate staging and treatment decisions in clinical practice.
Immunotherapy before surgery could transform lung cancer treatment: DZL researchers report in the NEOMUN study that pembrolizumab can significantly shrink tumors even prior to the procedure.
New insights into ALK fusions in lung cancer could help tailor therapies more precisely to the specific variant in the future. Researchers at the DKFZ have investigated the differences between the most common variants.
Latest research shows: despite ongoing challenges, the combination of innovative therapeutic strategies and precise diagnostics opens up new perspectives for people with advanced NSCLC.
A new study by DZL-scientists reveals how cancer-associated fibroblasts (CAFs), a key component of the tumor microenvironment, enable lung tumors to resist targeted therapies by rewiring cellular metabolism.
Using Impulse Oscillometry, early damage to the small airways can be detected—even before lung function shows a noticeable decline. This is the result of a study conducted by DZL scientists, designed as a companion study...
A team of DZL scientists at the TLRC site has made significant progress towards a reliable, minimally invasive prediction of therapy success in patients with advanced non-small cell lung cancer (NSCLC). The innovative approach uses...
The American Thoracic Society issues a statement led by Prof. Dr. Rajkumar Savai, highlighting the urgent need for further lung cancer research. The statement focuses on knowledge gaps and new opportunities for early detection of...
Prof. Dr. Rajkumar Savai explains in *Nature* how advanced spatial tumor analysis technologies can help better understand the limited effectiveness of immunotherapies and develop targeted treatment approaches for lung cancer.
Iron particles slow down the growth of non-small cell lung carcinoma. A team of researchers from Heidelberg demonstrated this in an animal model in a project funded by the DZL.
Tumor cells can use a messenger substance to prevent immune cells from attacking them. DZL researchers and their colleagues at the Technical University of Munich and LMU Hospital Munich discovered this.
